医学
索拉非尼
伦瓦提尼
瑞戈非尼
杜瓦卢马布
肝细胞癌
催眠药
卡波扎尼布
肿瘤科
内科学
贝伐单抗
阿替唑单抗
银耳霉素
全身疗法
外科肿瘤学
靶向治疗
无容量
癌症
易普利姆玛
免疫疗法
化疗
结直肠癌
乳腺癌
标识
DOI:10.1007/s10147-022-02166-0
摘要
Since the approval of sorafenib for the treatment of unresectable hepatocellular carcinoma in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and atezolizumab plus bevacizumab for first-line treatment, and regorafenib, cabozantinib, and ramucirumab for second-line treatment, which are currently available for clinical use. The positive results of durvalumab, a programmed cell death ligand 1 antibody, plus tremelimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, were also presented at the 2022 American Society Clinical Oncology Gastrointestinal Cancers Symposium as superior to sorafenib in prolonging the overall survival; this combination is expected to be approved by the end of 2022. These systemic therapies are changing the treatment paradigm not only for advanced hepatocellular carcinoma but also for intermediate-stage hepatocellular carcinoma. This review focuses on the role of systemic therapy in intermediate-stage hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI